CSF2 and irritable bowel syndrome: Except for eotaxin, which has become a novel therapeutic target in UC [27], eosinophil-associated cytokines, such as GM-CSF, IL3, IL5, and IL13, have not been comprehensively analyzed in the context of IBD.